For example, Erlotinib [an EGFR inhibitor used in the first line treatment of not small cell metastatic lung cancer (NSCL) showing exon deletions or mutations of EGFR] requires autophagy activation to maximize inhibition of tumor growth (Wei et al., 2013). The gene discussed is EGFR; the disease is neoplasm.